Plasma Phosphorylated Tau 217 Percentage by Race and Ethnicity in Preclinical Alzheimer Disease

Do plasma phosphorylated tau 217 percentage (%p-tau217) levels differ across self-reported race and ethnicity and apolipoprotein E ε4 (APOE ε4) status in a cohort of adults screened for preclinical Alzheimer disease (AD) trials? In this cross-sectional study including 15 612 participants, %p-tau217 levels were lower among Asian, Black, and Hispanic participants compared with White and non-Hispanic participants. APOE ε4 carrier status was associated with higher %p-tau217 levels across all groups. Plasma %p-tau217 varied across racial and ethnic groups; associations between APOE ε4 status and %p-tau217 differed across groups and may have implications for plasma screening strategies in preclinical AD trials.

Corresponding Author: Doris P. Molina-Henry, PhD, Epstein Family Alzheimer’s Therapeutic Research Institute, Keck School of Medicine of the University of Southern California, 9860 Mesa Rim Rd, San Diego, CA 92121 (molinahe@usc.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.